Stellate Therapeutics Inc. (“the Company”, “Stellate”), a global biotechnology company developing disease-modifying therapies based on molecules derived from the microbiome to treat neurological conditions, is pleased to announce the publication of data evaluating the efficacy of the Company’s microbiome-derived lead candidate, STL-101 (synthesized queuine) in in vitro experiments. The data, published in the peer-reviewed scientific journal PLOS ONE, demonstrate that STL-101 has neuroprotective properties.
that the AgriO Committee has labelled NovoBiome a ‘French Tech Seed’, paving the way for
NovoBiome to receive additional public fund.
-Pierre-Yves Mousset, Chief Executive Officer of NovoBiome, said: “We are thrilled to have
obtained this recognition by AgriO, which validates the potential of our disruptive ex-vivo
discovery platform. Moreover, it confirms the interest in the field of intestinal microbiota,
witnessing the close links between the two universes of health, and food and nutrition.”